News und Analysen

With the S&P 500 index recently hitting a new all-time high, we can officially declare that we are in a bull market. While that's exciting news, it doesn't change the blueprint of success for

What's the appeal of investing in relatively small and little-known corporations? Though these businesses come with heightened risks, getting in on the ground floor can potentially be lucrative over

Pfizer (NYSE: PFE) has reached a major transition point. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the first to launch a coronavirus vaccine. That

I'll readily admit that I've picked some supposed growth stocks in the past that didn't deliver much growth. The good news, though, is that my winners have far outpaced my losers over the long run.

UnitedHealth Group (NYSE: UNH) and Johnson & Johnson (NYSE: JNJ) are two of the largest healthcare companies in the world. One is focused on health insurance, while the other makes medical devices

Cancer bites, but Amgen (NASDAQ: AMGN) is going to keep biting back. In fact, it's currently developing a handful of oncology medicines that it describes as bispecific T-cell engager therapies, or

Time in the market beats timing the market, hands-down. But how long should you own a stock?

Famed investor Warren Buffett perhaps said it best: "When we own portions of outstanding businesses with

Shares of Humana (NYSE: HUM) are down 11.7% on Thursday after the health insurance giant announced weaker-than-expected quarterly results and light profit guidance for the coming year.

Humana's

Shares of ResMed (NYSE: RMD) were jumping 7% as of 11:25 a.m. ET on Thursday after rising as much as 10.6% earlier in the morning. The solid gain came after the medical device maker announced

Those who put money in Vertex Pharmaceuticals (NASDAQ: VRTX) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period.

However, a lot has changed for

Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for

Building a balanced portfolio requires careful planning and execution. You need to think about your long-term objectives for growth and income, as well as tax implications, when you need to adjust

As you build your portfolio through the years, you may find that you gravitate toward stocks across an assortment of sectors, with a range of risk profiles, growth stories, and businesses

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q4 2023 Earnings CallJan 24, 2024, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

It finally happened. About 10 years after being created, gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP) earned approval for its first therapy late last year. The treatment in question is

I can sum up Pfizer's (NYSE: PFE) stock performance over the last couple of years in one word (and only three letters): ugh. Shares of the big drugmaker have plunged more than 50% since the high set

Pfizer (NYSE: PFE) ended 2022 with a bang, delivering its highest level of revenue ever -- $100 billion -- thanks to its coronavirus vaccine and treatment. But the drop in demand for those products

Many stocks performed well last year, but Medtronic (NYSE: MDT) wasn't one of them. The medical device giant failed to keep pace with broader equities, partly because it was still dealing with

With CRISPR Therapeutics (NASDAQ: CRSP) in the news thanks to its successful work in developing cutting-edge gene therapies, it's easy to assume that everything in the business is going swimmingly

On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics, (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the

Every portfolio should include a few monster stocks, or companies with huge market share and staying power, and products likely to drive growth for the long term. Healthcare is a great place to look

Sarepta Therapeutics (NASDAQ: SRPT) saw a lot of love from the market as the trading week kicked off on Monday. Investors pushed the stock almost 5% higher in price, a move due in no small part to

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the fastest-growing healthcare companies in recent years. Its products have made it a leader in cystic fibrosis (CF) treatment and it has been

The new year is here, and for many, it's a fresh opportunity to set financial goals and find fresh stocks to consider adding to a portfolio. The types of stocks you gravitate toward will broadly be